Comparative Efficacy and Safety of Next-Generation JAK Inhibitors (Fedratinib, Pacritinib, and Momelotinib) in Myelofibrosis: A Systematic Review and Meta-Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-1057; Location: LEVEL 3, HALL B3; "While ruxolitinib remains the first-approved JAK inhibitor, three next-generation agents—fedratinib, pacritinib, and momelotinib—have since received regulatory approval, each addressing distinct unmet needs. Next-generation JAK inhibitors demonstrate significant and consistent efficacy over comparators in myelofibrosis. Fedratinib leads on spleen and symptom end points; momelotinib offers a unique and reproducible TI benefit in anemic patients; and pacritinib fills a critical therapeutic gap in severe thrombocytopenia. These findings support a precision-based, biomarker-informed treatment selection strategy, with anemia and platelet count serving as primary decision variables."
Retrospective data • Review • Myelofibrosis • Myeloproliferative Neoplasm • Oncology
|
|
Basil Joy MBBS 1; Jeffrey Mathew Boby MBBS 1; Esha Umair MBBS 2; Ajina Joy MBBS 1; Vijay Murali MBBS 3
|